Published in J Clin Pharmacol on January 10, 2008
Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 2.97
Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood (2012) 1.17
Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J (2009) 1.12
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol (2011) 1.01
PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics (2010) 0.90
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol (2008) 0.90
Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opin Drug Metab Toxicol (2012) 0.89
Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med (Zagreb) (2013) 0.89
Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Med Sci Monit (2015) 0.87
Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol (2013) 0.86
Personalized medicine in diabetes mellitus: current opportunities and future prospects. Ann N Y Acad Sci (2015) 0.83
Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol (2010) 0.83
Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics (2008) 0.81
Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol (2011) 0.81
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. Pharmgenomics Pers Med (2009) 0.81
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. Pharmgenomics Pers Med (2016) 0.79
Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur J Clin Pharmacol (2012) 0.79
A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients. Sci Rep (2016) 0.78
Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. Pharmacogenomics J (2016) 0.75
Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes (2016) 0.75
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet (2003) 3.37
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther (2006) 2.83
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev (2011) 2.08
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther (2002) 2.01
Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol (2005) 1.96
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther (2005) 1.74
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther (2004) 1.68
Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther (2004) 1.62
Out-of-hospital administration of activated charcoal by emergency medical services. Ann Emerg Med (2005) 1.52
Global analysis of genetic variation in SLCO1B1. Pharmacogenomics (2008) 1.47
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 1.42
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos (2002) 1.40
Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther (2002) 1.32
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther (2006) 1.30
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther (2003) 1.21
Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol (2002) 1.20
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol (2005) 1.15
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos (2002) 1.14
Prescription drugs during pregnancy and lactation--a Finnish register-based study. Eur J Clin Pharmacol (2003) 1.12
Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol (2007) 1.11
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol (2006) 1.11
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet (2008) 1.11
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther (2006) 1.10
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res (2006) 1.10
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol (2006) 1.09
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics (2011) 1.09
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther (2003) 1.08
Infections and possible vaccine-drug interactions. Eur J Clin Pharmacol (2014) 1.07
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics (2009) 1.07
Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther (2005) 1.07
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol (2006) 1.05
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol (2005) 1.04
Prescription of hazardous drugs during pregnancy. Drug Saf (2004) 1.02
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther (2012) 1.02
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos (2007) 1.02
Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol (2006) 1.02
Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome. Ann Thorac Surg (2013) 1.01
Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther (2004) 1.00
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics (2008) 0.99
Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol (2004) 0.99
Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol (2008) 0.98
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther (2006) 0.98
Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs Aging (2011) 0.98
Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther (2004) 0.98
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther (2005) 0.97
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci (2012) 0.97
Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs. Ann Emerg Med (2010) 0.97
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther (2003) 0.96
Intravenous lipid emulsion only minimally influences bupivacaine and mepivacaine distribution in plasma and does not enhance recovery from intoxication in pigs. Anesth Analg (2011) 0.96
Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther (2004) 0.96
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol (2006) 0.96
Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology (2009) 0.96
Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol (2006) 0.95
Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol (2007) 0.94
Acetaminophen improves analgesia but does not reduce opioid requirement after major spine surgery in children and adolescents. Spine (Phila Pa 1976) (2012) 0.94
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics (2008) 0.93
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics (2005) 0.92
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther (2005) 0.92
Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol (2011) 0.91
Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenet Genomics (2009) 0.91
Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clin Pharmacol Ther (2003) 0.91
Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol (2004) 0.90
Drug-related visits to a district hospital emergency room. Basic Clin Pharmacol Toxicol (2006) 0.90
High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.90
Statins and hip fracture prevention--a population based cohort study in women. PLoS One (2012) 0.90